Yiping Zhang

Nivolumab Versus Docetaxel in a Predominantly Chinese Patient Population With Previously Treated Advanced NSCLC: CheckMate 078 Randomized Phase III Clinical Trial

Yi‐Long Wu, Shun Lü, Ying Cheng et al. · Journal of Thoracic Oncology · 2019 · 358 citations

Medicine, Oncology, Pharmacology +17

Overall survival (OS) results from OPTIMAL (CTONG0802), a phase III trial of erlotinib (E) versus carboplatin plus gemcitabine (GC) as first-line treatment for Chinese patients with <i>EGFR</i> mutation-positive advanced non-small cell lung cancer (NSCLC).

Caicun Zhou, Yi‐Long Wu, Xiaoqing Liu et al. · Journal of Clinical Oncology · 2012 · 79 citations

Medicine, Pharmacology, Cancer Pharmacology +7

NiO-Co 3 O 4 nanoplate composite as efficient anode in Li-ion battery

Yiping Zhang, Qiqi Zhuo, Xiaoxin Lv et al. · Electrochimica Acta · 2015 · 69 citations

Natural Sciences, Materials Engineering, Materials Science +17

Allyl(β-diketonato)palladium(II) Complexes, Including Liquid Precursors, for Chemical Vapor Deposition of Palladium

Yiping Zhang, Zheng Yuan, Richard J. Puddephatt · Chemistry of Materials · 1998 · 49 citations

Natural Sciences, Chemical Engineering, Chemistry +12

A Multicenter, Open-Label, Randomized Phase II Controlled Study of rh-Endostatin (Endostar) in Combination with Chemotherapy in Previously Untreated Extensive-Stage Small-Cell Lung Cancer

Shun Lu, Li Lü, Yi Luo et al. · Journal of Thoracic Oncology · 2015 · 44 citations · Full text

Medicine, Oncology, Pharmacology +8